Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
BioNTech SE and OncoC4 Inc. released first median overall survival results from stage 1 of the PRESERVE-003 Phase 3 trial for gotistobart, reporting nearly doubled survival versus standard chemotherapy in a specific patient population and citing a stock jump of about 2%.
The companies said updated results from PRESERVE-003 stage 1 show gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients, and they announced first median OS data from stage 1.